Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 1 |
| Top Partnership Deal Terminations Introduction | 10 | 2 |
| Licensing Agreement An Authorization | 10 | 1 |
| Termination of Licensing Agreements | 10 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Top Partnership Deal Terminations Trends | 12 | 4 |
| Reasons for Deal Terminations | 12 | 1 |
| Therapeutic Areas Terminated Deals | 13 | 1 |
| Deal Values Terminated Deals | 14 | 2 |
| Top Partnership Deal Terminations - Deals | 16 | 99 |
| GlaxoSmithKline Terminates Licensing Agreement with Actelion for Almorexant | 16 | 1 |
| Companies Overview | 16 | 1 |
| GlaxoSmithKline | 16 | 1 |
| Actelion | 17 | 1 |
| Product Overview | 17 | 1 |
| Clinical Trial Details | 18 | 1 |
| Deal Overview | 19 | 1 |
| Deal Value | 19 | 1 |
| Deal Rationale | 19 | 1 |
| Reason for Termination | 20 | 1 |
| GlaxoSmithKline Terminates Co-Development Agreement with Targacept for Development of Neuronal Nicotinic Receptor Therapeutics | 20 | 1 |
| Companies Overview | 21 | 1 |
| GlaxoSmithKline | 21 | 1 |
| Targacept | 21 | 1 |
| Product Overview | 21 | 1 |
| Clinical Trial Details - TC-2696 | 22 | 1 |
| Clinical Trial Details TC-6499 | 22 | 1 |
| Deal Overview | 23 | 1 |
| Deal Value | 23 | 1 |
| Deal Rationale | 23 | 1 |
| Reason for Termination | 23 | 1 |
| Shire Terminates Licensing Agreement with Renovo Group for Juvista | 24 | 1 |
| Companies Overview | 24 | 1 |
| Shire Plc | 24 | 1 |
| Renovo Group Plc | 25 | 1 |
| Product Overview | 26 | 1 |
| Clinical Trial Details | 26 | 2 |
| Deal Overview | 28 | 1 |
| Deal Value | 28 | 1 |
| Deal Rationale | 28 | 1 |
| Reason for Termination | 28 | 1 |
| Anacor Pharmaceuticals Terminates Licensing Agreement with Merck for AN2690 | 29 | 1 |
| Companies Overview | 29 | 1 |
| Anacor Pharmaceuticals | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| Product Overview | 31 | 1 |
| Clinical Trial Details | 31 | 3 |
| Deal Overview | 34 | 1 |
| Deal Value | 34 | 1 |
| Deal Rationale | 34 | 1 |
| Reason for Termination | 34 | 1 |
| Novartis Terminates Licensing Agreement with Human Genome Sciences for Albuferon | 35 | 1 |
| Companies Overview | 35 | 1 |
| Novartis AG | 35 | 1 |
| Human Genome Sciences, Inc. | 36 | 1 |
| Product Overview | 37 | 1 |
| Clinical Trial Details | 37 | 1 |
| Deal Overview | 38 | 1 |
| Deal Value | 38 | 1 |
| Deal Rationale | 38 | 1 |
| Reason for Termination | 39 | 1 |
| InterMune Terminates Licensing Agreement with F. Hoffmann-La Roche for ITMN-191 | 39 | 1 |
| Companies Overview | 40 | 1 |
| InterMune, Inc. | 40 | 1 |
| F. Hoffmann-La Roche Ltd. | 40 | 2 |
| Product Overview | 42 | 1 |
| Clinical Trial Details | 42 | 1 |
| Deal Overview | 43 | 1 |
| Deal Value | 44 | 1 |
| Deal Rationale | 44 | 1 |
| Reason for Termination | 44 | 1 |
| GTx Terminates Worldwide Licensing Agreement with Merck for Ostarine | 45 | 1 |
| Companies Overview | 45 | 1 |
| GTx, Inc. | 45 | 1 |
| Merck &Co., Inc. | 46 | 1 |
| Product Overview | 46 | 1 |
| Clinical Trial Details | 46 | 2 |
| Deal Overview | 48 | 1 |
| Deal Value | 48 | 1 |
| Deal Rationale | 48 | 1 |
| Reason for Termination | 48 | 1 |
| Aveo Pharmaceuticals Terminates Licensing Agreement with Merck for AV-299 | 49 | 1 |
| Companies Overview | 49 | 1 |
| Aveo Pharmaceuticals, Inc. | 49 | 1 |
| Merck &Co. | 49 | 1 |
| Product Overview | 50 | 1 |
| Clinical Trial Details | 51 | 2 |
| Deal Overview | 53 | 1 |
| Deal Value | 53 | 1 |
| Deal Rationale | 53 | 1 |
| Reason for Termination | 53 | 1 |
| Merck KGaA Terminates Worldwide Licensing Agreement with Lpath for Asonep | 54 | 1 |
| Companies Overview | 54 | 1 |
| Merck KGaA | 54 | 1 |
| Lpath, Inc. | 55 | 1 |
| Product Overview | 56 | 1 |
| Clinical Trial Details | 56 | 1 |
| Deal Overview | 57 | 1 |
| Deal Value | 57 | 1 |
| Deal Rationale | 57 | 1 |
| Reason for Termination | 57 | 1 |
| Portola Pharmaceuticals Terminates Licensing Agreement with Merck for Betrixaban | 58 | 1 |
| Companies Overview | 58 | 1 |
| Portola Pharmaceuticals, Inc. | 58 | 1 |
| Merck &Co. | 58 | 1 |
| Product Overview | 59 | 1 |
| Clinical Trial Details | 59 | 2 |
| Deal Overview | 61 | 1 |
| Deal Value | 61 | 1 |
| Deal Rationale | 61 | 1 |
| Reason for Termination | 61 | 1 |
| Celldex Therapeutics Terminates Licensing Agreement with Pfizer for Rindopepimut | 62 | 1 |
| Companies Overview | 62 | 1 |
| Celldex Therapeutics, Inc | 62 | 1 |
| Pfizer Inc. | 63 | 1 |
| Product Overview | 63 | 1 |
| Clinical Trial Details | 64 | 2 |
| Deal Overview | 66 | 1 |
| Deal Value | 66 | 1 |
| Deal Rationale | 66 | 1 |
| Reason for Termination | 66 | 1 |
| Depomed Terminates Licensing Agreement with Abbott Laboratories for DM-1796 | 67 | 1 |
| Companies Overview | 67 | 1 |
| Depomed Inc. | 67 | 1 |
| Abbott Laboratories | 68 | 2 |
| Product Overview | 70 | 1 |
| Clinical Trial Details | 70 | 3 |
| Deal Overview | 73 | 1 |
| Deal Value | 73 | 1 |
| Deal Rationale | 73 | 1 |
| Reason for Termination | 73 | 1 |
| Sanofi Terminates Licensing Agreement with Metabolex for MBX-2982 | 74 | 1 |
| Companies Overview | 74 | 1 |
| Sanofi | 74 | 1 |
| Metabolex, Inc. | 75 | 1 |
| Product Overview | 75 | 1 |
| Clinical Trial Details | 75 | 1 |
| Deal Overview | 76 | 1 |
| Deal Value | 76 | 1 |
| Deal Rationale | 76 | 1 |
| Reason for Termination | 76 | 1 |
| BioLineRx Terminates Licensing Agreement with Cypress Bioscience for BL-1020 | 77 | 1 |
| Companies Overview | 78 | 1 |
| BioLineRx, Ltd. | 78 | 1 |
| Cypress Bioscience, Inc. | 78 | 1 |
| Product Overview | 79 | 1 |
| Clinical Trial Details | 79 | 3 |
| Deal Overview | 82 | 1 |
| Deal Value | 82 | 1 |
| Deal Rationale | 82 | 1 |
| Reason for Termination | 83 | 1 |
| Cilag Terminates Licensing Agreement with Basilea Pharmaceutica for Ceftobiprole | 83 | 1 |
| Companies Overview | 84 | 1 |
| Janssen-Cilag EMEA | 84 | 1 |
| Basilea Pharmaceutica Ltd. | 84 | 1 |
| Product Overview | 85 | 1 |
| Clinical Trial Details | 85 | 1 |
| Deal Overview | 86 | 1 |
| Deal Value | 86 | 1 |
| Deal Rationale | 86 | 1 |
| Reason for Termination | 87 | 1 |
| Roche Terminates Licensing Agreement with Ipsen for Taspoglutide | 87 | 1 |
| Companies Overview | 88 | 1 |
| F. Hoffmann-La Roche Ltd. | 88 | 1 |
| Ipsen S.A. | 88 | 1 |
| Product Overview | 88 | 1 |
| Clinical Trial Details | 88 | 7 |
| Deal Overview | 95 | 1 |
| Deal Value | 95 | 1 |
| Deal Rationale | 95 | 1 |
| Reason for Termination | 95 | 1 |
| Roche Terminates Licensing Agreement with Transgene for Papilloma Vaccine TG4001 | 96 | 1 |
| Companies Overview | 96 | 1 |
| Transgene SA | 96 | 1 |
| F. Hoffmann-La Roche Ltd. | 96 | 1 |
| Product Overview | 97 | 1 |
| Clinical Trial Details | 97 | 1 |
| Deal Overview | 97 | 1 |
| Deal Value | 97 | 1 |
| Deal Rationale | 98 | 1 |
| Reason for Termination | 98 | 1 |
| Rigel Pharmaceuticals Terminates Licensing Agreement with Pfizer for R343 | 98 | 1 |
| Companies Overview | 99 | 1 |
| Rigel Pharmaceuticals, Inc. | 99 | 1 |
| Pfizer Inc. | 99 | 1 |
| Product Overview | 100 | 1 |
| Clinical Trial Details | 100 | 1 |
| Deal Overview | 100 | 1 |
| Deal Value | 100 | 1 |
| Deal Rationale | 100 | 1 |
| Reason for Termination | 100 | 1 |
| Abbott Laboratories Terminates Licensing Agreement with SkyePharma for Flutiform | 101 | 1 |
| Companies Overview | 102 | 1 |
| Abbott Laboratories | 102 | 1 |
| SkyePharma PLC | 102 | 1 |
| Product Overview | 103 | 1 |
| Clinical Trial Details | 103 | 5 |
| Deal Overview | 108 | 1 |
| Deal Value | 108 | 1 |
| Deal Rationale | 108 | 1 |
| Reason for Termination | 108 | 1 |
| Merck Terminates Strategic Alliance with Intercell for V710 | 109 | 1 |
| Companies Overview | 109 | 1 |
| Intercell AG | 109 | 1 |
| Merck &Co., Inc. | 110 | 1 |
| Product Overview | 110 | 1 |
| Clinical Trial Details | 110 | 4 |
| Deal Overview | 114 | 1 |
| Deal Value | 114 | 1 |
| Deal Rationale | 114 | 1 |
| Reason for Termination | 114 | 1 |
| Top Partnership Deal Terminations - Appendix | 115 | 5 |
| Market Definitions | 115 | 1 |
| Abbreviations | 115 | 2 |
| Research Methodology | 117 | 3 |
| Coverage | 117 | 1 |
| Secondary Research | 118 | 1 |
| Primary Research | 118 | 1 |
| Section-wise Research Methodology | 118 | 1 |
| Trends | 118 | 1 |
| Deals | 119 | 1 |
| Expert Panel Validation | 119 | 1 |
| Contact Us | 119 | 1 |
| Disclaimer | 119 | 1 |
| Sources | 119 | 1 |